Barinthus Biotherapeutics (BRNS) Competitors $1.10 -0.03 (-2.65%) Closing price 09/12/2025 03:50 PM EasternExtended Trading$1.10 0.00 (-0.36%) As of 09/12/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BRNS vs. CCCC, SXTC, ENTA, EPRX, TLSA, IPHA, DERM, NLTX, BIOA, and MDWDShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include C4 Therapeutics (CCCC), China SXT Pharmaceuticals (SXTC), Enanta Pharmaceuticals (ENTA), Eupraxia Pharmaceuticals (EPRX), Tiziana Life Sciences (TLSA), Innate Pharma (IPHA), Journey Medical (DERM), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), and MediWound (MDWD). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Its Competitors C4 Therapeutics China SXT Pharmaceuticals Enanta Pharmaceuticals Eupraxia Pharmaceuticals Tiziana Life Sciences Innate Pharma Journey Medical Neoleukin Therapeutics BioAge Labs MediWound Barinthus Biotherapeutics (NASDAQ:BRNS) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment. Which has more risk & volatility, BRNS or CCCC? Barinthus Biotherapeutics has a beta of -0.75, meaning that its stock price is 175% less volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.98, meaning that its stock price is 198% more volatile than the S&P 500. Which has preferable valuation & earnings, BRNS or CCCC? Barinthus Biotherapeutics has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBarinthus Biotherapeutics$14.97M2.99-$61.07M-$1.73-0.64C4 Therapeutics$34.24M5.53-$105.32M-$1.58-1.68 Is BRNS or CCCC more profitable? Barinthus Biotherapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -325.88%. C4 Therapeutics' return on equity of -53.91% beat Barinthus Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Barinthus BiotherapeuticsN/A -54.70% -44.75% C4 Therapeutics -325.88%-53.91%-33.26% Do institutionals & insiders hold more shares of BRNS or CCCC? 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 10.7% of Barinthus Biotherapeutics shares are owned by insiders. Comparatively, 8.7% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts prefer BRNS or CCCC? Barinthus Biotherapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 172.73%. C4 Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 200.75%. Given C4 Therapeutics' higher probable upside, analysts plainly believe C4 Therapeutics is more favorable than Barinthus Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00C4 Therapeutics 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Does the media refer more to BRNS or CCCC? In the previous week, C4 Therapeutics had 2 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for C4 Therapeutics and 1 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 1.91 beat C4 Therapeutics' score of 1.62 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Barinthus Biotherapeutics Very Positive C4 Therapeutics Very Positive SummaryC4 Therapeutics beats Barinthus Biotherapeutics on 9 of the 15 factors compared between the two stocks. Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.01M$3.19B$5.84B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-0.6421.4375.4125.98Price / Sales2.99429.44515.81181.13Price / CashN/A46.6837.5660.44Price / Book0.349.6112.156.29Net Income-$61.07M-$53.29M$3.29B$271.07M7 Day Performance-11.29%0.13%0.74%3.87%1 Month Performance-13.79%5.55%5.00%5.49%1 Year Performance-13.39%10.44%62.53%25.86% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics2.9858 of 5 stars$1.10-2.7%$3.00+172.7%-14.1%$46.01M$14.97M-0.64107Positive NewsGap UpHigh Trading VolumeCCCCC4 Therapeutics2.8771 of 5 stars$2.68-1.1%$8.00+198.5%-58.7%$192.87M$35.58M-1.70150SXTCChina SXT Pharmaceuticals1.3002 of 5 stars$1.48-10.6%N/A-62.8%$191.45M$1.74M0.0090Positive NewsShort Interest ↓ENTAEnanta Pharmaceuticals4.175 of 5 stars$9.04+1.5%$22.25+146.1%-33.4%$190.48M$67.64M-2.09160EPRXEupraxia Pharmaceuticals2.8629 of 5 stars$5.270.0%$11.00+108.8%+106.6%$189.51MN/A-6.2029News CoverageTLSATiziana Life Sciences0.5561 of 5 stars$1.85+14.2%N/A+82.7%$189.29MN/A0.008Short Interest ↑IPHAInnate Pharma3.0128 of 5 stars$2.04flat$11.00+439.2%-11.5%$188.05M$21.77M0.00220Positive NewsUpcoming EarningsDERMJourney Medical2.392 of 5 stars$7.45+6.3%$12.17+63.3%+37.8%$184.43M$56.40M-19.6190Positive NewsNLTXNeoleukin TherapeuticsN/A$19.45-2.5%N/A-54.7%$182.79MN/A-6.2590High Trading VolumeBIOABioAge Labs0.1936 of 5 stars$4.98-2.2%N/AN/A$182.48MN/A0.00N/APositive NewsMDWDMediWound1.6369 of 5 stars$16.29-2.7%$32.25+98.0%+0.8%$180.92M$20.22M-6.1780 Related Companies and Tools Related Companies CCCC Competitors SXTC Competitors ENTA Competitors EPRX Competitors TLSA Competitors IPHA Competitors DERM Competitors NLTX Competitors BIOA Competitors MDWD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BRNS) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BRNS Stock Alerts